Pituitary

, 11:279

Correction of cortisol overreplacement ameliorates morbidities in patients with hypopituitarism: a pilot study

  • Karina Danilowicz
  • Oscar Domingo Bruno
  • Marcos Manavela
  • Reynaldo Manuel Gomez
  • Ariel Barkan
Article

Abstract

Context Hyporituitarism in adults is known to be associated with deleterious effects on body composition, lipid profile and quality of life (QoL). This was attributed to GH deficiency. The potential role of glucocorticoid overreplacement had never been investigated. Objective To investigate whether reduction in glucocorticoid replacement dose to more physiological one could ameliorate the “AO-GHD”-attributed symptomatology in patients with hypopituitarism. Design Eleven patients with panhypopituitarism taking 20–30 mg/day of hydrocortisone, but on no GH replacement were switched to 10–15 mg of hydrocortisone daily. Both basally and 6–12 months later, their body mass index, body composition by dual-energy X-ray absorptiometry, lipid profile, and the score of quality of life, QOL-AGHDA were measured. Results Within 6–12 months of lower hydrocortisone dose, subjects lost an average of 7.1 kg of total body fat and 4.1 kg of abdominal fat. No changes were seen in lean body mass, bone mineral content and HOMA-IR. Plasma total cholesterol and triglyceride concentrations decreased significantly (<0.05) and the QoL improved (P = 0.018). Conclusions Our pilot study suggests that decreasing the glucocorticoid replacement dose to ~15 mg/day is beneficial in terms of patients’ body composition, lipid profile and quality of life.

Keywords

Hypopituitarism Cortisol replacement Growth hormone deficiency 

References

  1. 1.
    Malik IA, Foy P, Wallymahmed M, Wilding JP, MacFarlane IA (2003) Assessment of quality of life in adults receiving long-term growth hormone replacement compared to control subjects. Clin Endocrinol (Oxf) 59:75–81. doi:10.1046/j.1365-2265.2003.01799.x CrossRefGoogle Scholar
  2. 2.
    Attanasio AF, Bates PC, Ho KK et al (2002) Hypoptiuitary control and complications study international advisory board. Human growth hormone replacement in adult hypopituitary patients: long-term effects on body composition and lipid status-3-year results from the HypoCCS Database. J Clin Endocrinol Metab 87:1600–1606. doi:10.1210/jc.87.4.1600 PubMedCrossRefGoogle Scholar
  3. 3.
    Besser GM, Jeffcoate WJ (1976) Endocrine and metabolic diseases. Adrenal diseases. BMJ 1:448–451PubMedGoogle Scholar
  4. 4.
    Groves RW, Toms GC, Houghton BJ, Monson JP (1988) Corticosteroid replacement therapy: twice or thrice daily? J R Soc Med 81:514–516PubMedGoogle Scholar
  5. 5.
    Johannsson G, Rosén T, Bosaeus I, Sjöström L, Bengtsson BA (1996) Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. J Clin Endocrinol Metab 81:2865–2873. doi:10.1210/jc.81.8.2865 PubMedCrossRefGoogle Scholar
  6. 6.
    Filipsson H, Monson JP, Koltowska-Haggstrom M, Mattsson A, Johannsson GJ (2006) The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab 91:3954–3961. doi:10.1210/jc.2006-0524 PubMedCrossRefGoogle Scholar
  7. 7.
    Colao A, Di Somma C, Rota F et al (2005) Short-term effects of growth hormone (GH) treatment or deprivation on cardiovascular risk parameters and intima-media thickness at carotid arteries in patients with severe GH deficiency. J Clin Endocrinol Metab 90:2056–2062. doi:10.1210/jc.2004-2247 PubMedCrossRefGoogle Scholar
  8. 8.
    Esteban NV, Loughlin T, Yergey AZ et al (1991) Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J Clin Endocrinol Metab 72:1698–1700Google Scholar
  9. 9.
    McKenna SP, Doward LC, Alonso J et al (1999) The Qol-AGHDA: an instrument for the assessment of quality of life in adults with growth hormone deficiency. Qual Life Res 4:373–338. doi:10.1023/A:1008987922774 CrossRefGoogle Scholar
  10. 10.
    Rosen T, Bengtsson BA (1990) Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336:285–288. doi:10.1016/0140-6736(90) 91812-O PubMedCrossRefGoogle Scholar
  11. 11.
    Beshyah SA, Freemantle C, Thomas E et al (1995) Abnormal body composition and reduced bone mass in growth hormone deficient hypopituitary adults. Clin Endocrinol (Oxf) 42:179–189. doi:10.1111/j.1365-2265.1995.tb01860.x CrossRefGoogle Scholar
  12. 12.
    Hoffman AR, Kuntze JE, Baptista J et al (2004) Growth hormone (GH) replacement therapy in adult-onset GH deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 89:2048–2056. doi:10.1210/jc.2003-030346 PubMedCrossRefGoogle Scholar
  13. 13.
    Mauras N, Pescovitz OH, Allada V, Messig M, Wajnrajch MP, Lippe B, Transition Study Group (2005) Limited efficacy of growth hormone (GH) during transition of GH-deficient patients from adolescence to adulthood: a phase III multicenter, double-blind, randomized two-year trial. J Clin Endocrinol Metab 90:3946–3955. doi:10.1210/jc.2005-0208 PubMedCrossRefGoogle Scholar
  14. 14.
    Christopher M, Hew FL, Oakley M, Rantzau C, Alford F (1998) Defects of insulin action and skeletal muscle glucose metabolism in growth hormone-deficient adults persist after 24 months of recombinant human growth hormone therapy. J Clin Endocrinol Metab 83:1668–1681. doi:10.1210/jc.83.5.1668 PubMedCrossRefGoogle Scholar
  15. 15.
    Sesmilo G, Biller BM, Llevadot J et al (2000) Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med 133:111–122PubMedGoogle Scholar
  16. 16.
    Cuneo RC, Judd S, Wallace JD et al (1998) The Australian multicenter trial of growth hormone (GH) treatment in GH-deficient adults. J Clin Endocrinol Metab 83:107–116. doi:10.1210/jc.83.1.107 PubMedCrossRefGoogle Scholar
  17. 17.
    Murray RD, Adams JE, Shalet SM (2006) A densitometric and morphometric analysis of the skeleton in adults with varying degrees of growth hormone deficiency. J Clin Endocrinol Metab 91:432–438. doi:10.1210/jc.2005-0897 PubMedCrossRefGoogle Scholar
  18. 18.
    Ehrnborg C, Ellegard L, Bosaeus I, Bengtsson BA, Rosen T (2005) Supraphysiological growth hormone: less fat, more extracellular fluid but uncertain effects on muscles in healthy, active young adults. Clin Endocrinol (Oxf) 62:449–457. doi:10.1111/j.1365-2265.2005.02240.x CrossRefGoogle Scholar
  19. 19.
    Kerrigan JR, Veldhuis JD, Leyo SA, Iranmanesh A, Rogol AD (1993) Estimation of daily cortisol production and clearance rates in normal pubertal males by deconvolution analysis. J Clin Endocrinol Metab 76:1505–1510. doi:10.1210/jc.76.6.1505 PubMedCrossRefGoogle Scholar
  20. 20.
    Hahner S, Loeffler M, Fassnacht M et al (2007) Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. J Clin Endocrinol Metab 92:3912–3922. doi:10.1210/jc.2007-0685 PubMedCrossRefGoogle Scholar
  21. 21.
    Dunne FP, Elliot P, Gammage MD et al (1995) Cardiovascular function and glucocorticoid replacement in patients with hypopituitarism. Clin Endocrinol (Oxf) 43:623–629. doi:10.1111/j.1365-2265.1995.tb02928.x CrossRefGoogle Scholar
  22. 22.
    Zeiger MA, Fraker DL, Pass HI et al (1993) Effective reversibility of the signs and symptoms of hypercortisolism by bilateral adrenalectomy. Surgery 114:1138–1143PubMedGoogle Scholar
  23. 23.
    Peacey SR, Guo CY, Robinson AM et al (1997) Glucocorticoid replacement therapy: are patients over treated and does it matter? Clin Endocrinol (Oxf) 46:255–261. doi:10.1046/j.1365-2265.1997.780907.x CrossRefGoogle Scholar
  24. 24.
    Hartman ML, Crowe BJ, Biller BM, Ho KK, Clemmons DR, Chipman JJ, HyposCCS Advisory Board U.S. HypoCCS Study Group (2002) Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency? J Clin Endocrinol Metab 87:477–485. doi:10.1210/jc.87.2.477 PubMedCrossRefGoogle Scholar
  25. 25.
    Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM, West of Scotland Coronary Prevention Study Group (2007) Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 357:1477–1486. doi:10.1056/NEJMoa065994 PubMedCrossRefGoogle Scholar
  26. 26.
    Taskinen MR, Nikkilä EA, Pelkonen R, Sane T (1983) Plasma lipoproteins, lipolytic enzymes, and very low density lipoprotein triglyceride turnover in Cushing’s syndrome. J Clin Endocrinol Metab 57:619–626PubMedCrossRefGoogle Scholar
  27. 27.
    Krsek M, Silha JV, Jezková J et al (2004) Adipokine levels in Cushing’s syndrome; elevated resistin levels in female patients with Cushing’s syndrome. Clin Endocrinol (Oxf) 60:350–357. doi:10.1111/j.1365-2265.2003.01987.x CrossRefGoogle Scholar
  28. 28.
    Pirlich M, Biering H, Gerl H et al (2002) Loss of body cell mass in Cushing’s syndrome: effect of treatment. J Clin Endocrinol Metab 87:1078–1084. doi:10.1210/jc.87.3.1078 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Karina Danilowicz
    • 1
  • Oscar Domingo Bruno
    • 1
  • Marcos Manavela
    • 1
  • Reynaldo Manuel Gomez
    • 1
    • 2
  • Ariel Barkan
    • 3
  1. 1.Division of EndocrinologyHospital de ClínicasCiudad Autónoma de Buenos AiresArgentina
  2. 2.Diagnóstico Médico SRLBuenos AiresArgentina
  3. 3.Division of Metabolism, Endocrinology and DiabetesUniversity of MichiganAnn ArborUSA

Personalised recommendations